Michael Girardi, MD

Michael Girardi, MD, is the director of Yale Medicine Dermatology’s ECP (Photopheresis) Immunotherapy Program, which is internationally recognized for developing the immunotherapy treatment photopheresis for advanced cutaneous T-cell lymphoma, graft-versus host disease, and organ transplant rejection.

“What I strive to do in the clinic and in the lab is to use technology to relieve suffering and help people who sometimes feel hopeless,” Dr. Girardi says.

A professor of dermatology at Yale School of Medicine, Dr. Girardi studies skin cancer and skin lymphoma and has received multiple innovation awards as a developer of new treatments for both cancer types. “I hope these technologies will one day make cancer treatments safer and more effective,” Dr. Girardi says.

Impacting skin cancer is important to Dr. Girardi on a personal level, too, after losing a family member to malignant melanoma as a child. “There is no doubt that the experience has stayed with me and has motivated me to help cancer patients in multiple ways,” he says.

“Ultimately, having a positive effect on patients' lives is what matters the most to me.”